Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2016

01-11-2016

Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients

Authors: Giulia Berti de Marinis, Stefano Novello, Silvia Ferrari, Isabella Barzon, Irene Cortella, Maria Antonietta Businaro, Fabrizio Fabris, Anna Maria Lombardi

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2016

Login to get access

Abstract

Differential diagnosis between thrombotic thrombocytopenic purpura (TTP) and other thrombotic microangiopathies (TMA) is usually difficult because of frequently overlapping clinical presentations. Severely depressed ADAMTS13 activity (<10 %) seems distinctive for TTP because of its pathogenetic role. However a long debate exists in the literature about its sensibility and specificity. Our aim was to search for clinical differences between TMA patients referred to our laboratory, comparing them for protease activity <10 versus ≥10 %. ADAMTS13 activity ≥10 % patients (n = 73) showed a higher prevalence of drug- (p = 0.005) and cancer-associated (p < 0.001) TMA. Mean platelet count and renal dysfunction prevalence was lower (p < 0.001), while neurological impairment was more frequent (p = 0.001) in the <10 % ADAMTS13 activity group (n = 109), confirming previous literature findings. When taken neurological manifestations singularly, epilepsy (p = 0.04), focal motor deficit (p < 0.001) and cranial nerve palsy (p = 0.007) were more frequent in the <10 % activity group. In our case series, a <10 % ADAMTS13 activity depicts a group of patients with clinical features similar to TTP patients. Focal motor impairment or epileptic manifestations could further address toward a TTP diagnosis. Studies about treatment efficacy and follow-up are advised to determine whether laboratory findings can guide therapeutic decisions.
Literature
1.
go back to reference Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. canadian apheresis study group. N Engl J Med 325(6):393–397CrossRefPubMed Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. canadian apheresis study group. N Engl J Med 325(6):393–397CrossRefPubMed
2.
go back to reference Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S et al (2008) Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 142(5):819–826CrossRefPubMed Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S et al (2008) Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 142(5):819–826CrossRefPubMed
3.
go back to reference Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339(22):1578–1584CrossRefPubMed Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339(22):1578–1584CrossRefPubMed
4.
go back to reference Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339(22):1585–1594CrossRefPubMedPubMedCentral Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339(22):1585–1594CrossRefPubMedPubMedCentral
5.
go back to reference Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413(6855):488–494CrossRefPubMed Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413(6855):488–494CrossRefPubMed
6.
go back to reference Lombardi AM, Fabris R, Scarda A, Zanato V, Dal Prà C, Scarparo P et al (2012) Presence of anti-ADAMTS13 antibodies in obesity. Eur J Clin Invest 42(11):1197–1204CrossRefPubMed Lombardi AM, Fabris R, Scarda A, Zanato V, Dal Prà C, Scarparo P et al (2012) Presence of anti-ADAMTS13 antibodies in obesity. Eur J Clin Invest 42(11):1197–1204CrossRefPubMed
7.
go back to reference Scheiflinger F, Knöbl P, Trattner B, Plaimauer B, Mohr G, Dockal M et al (2003) Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 102(9):3241–3243CrossRefPubMed Scheiflinger F, Knöbl P, Trattner B, Plaimauer B, Mohr G, Dockal M et al (2003) Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 102(9):3241–3243CrossRefPubMed
8.
go back to reference Tripodi A, Peyvandi F, Chantarangkul V, Palla R, Afrasiabi A, Canciani MT et al (2008) Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 6(9):1534–1541CrossRefPubMed Tripodi A, Peyvandi F, Chantarangkul V, Palla R, Afrasiabi A, Canciani MT et al (2008) Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 6(9):1534–1541CrossRefPubMed
9.
go back to reference Barrows BD, Teruya J (2014) Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura. Arch Pathol Lab Med 138(4):546–549CrossRefPubMed Barrows BD, Teruya J (2014) Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura. Arch Pathol Lab Med 138(4):546–549CrossRefPubMed
10.
go back to reference Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E (2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98(9):2730–2735CrossRefPubMed Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E (2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98(9):2730–2735CrossRefPubMed
11.
go back to reference Sánchez-Luceros A, Farías CE, Amaral MM, Kempfer AC, Votta R, Marchese C et al (2004) von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 92(6):1320–1326PubMed Sánchez-Luceros A, Farías CE, Amaral MM, Kempfer AC, Votta R, Marchese C et al (2004) von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 92(6):1320–1326PubMed
12.
go back to reference Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA et al (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102(1):60–68CrossRefPubMed Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA et al (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102(1):60–68CrossRefPubMed
13.
go back to reference George JN (2015) Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why? Transfusion 55(1):11–13CrossRefPubMedPubMedCentral George JN (2015) Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why? Transfusion 55(1):11–13CrossRefPubMedPubMedCentral
14.
go back to reference Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129:93–100CrossRefPubMed Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129:93–100CrossRefPubMed
15.
go back to reference Bendapudi PK, Li A, Hamdan A, Uhl L, Kaufman R, Stowell C et al (2015) Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the harvard TMA research collaborative. Br J Haematol 171:836–844CrossRefPubMed Bendapudi PK, Li A, Hamdan A, Uhl L, Kaufman R, Stowell C et al (2015) Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the harvard TMA research collaborative. Br J Haematol 171:836–844CrossRefPubMed
16.
go back to reference Shah N, Rutherford C, Matevosyan K, Shen YM, Sarode R (2013) Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 163(4):514–519CrossRefPubMed Shah N, Rutherford C, Matevosyan K, Shen YM, Sarode R (2013) Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 163(4):514–519CrossRefPubMed
17.
go back to reference Kremer Hovinga JA (2010) Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115(8):1500–1511CrossRefPubMed Kremer Hovinga JA (2010) Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115(8):1500–1511CrossRefPubMed
18.
go back to reference Rurali E, Banterla F, Donadelli R, Bresin E, Galbusera M, Gastoldi S, Peyvandi F, Underwood M, Remuzzi G, Noris M (2015) ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. Clin J Am Soc Nephrol 10(11):2002–2012CrossRefPubMed Rurali E, Banterla F, Donadelli R, Bresin E, Galbusera M, Gastoldi S, Peyvandi F, Underwood M, Remuzzi G, Noris M (2015) ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. Clin J Am Soc Nephrol 10(11):2002–2012CrossRefPubMed
19.
go back to reference Zafrani L, Mariotte E, Darmon M, Canet E, Merceron S, Boutboul D, Veyradier A, Galicier L, Azoulay E (2015) Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. J Thromb Haemost 13(3):380–389CrossRefPubMed Zafrani L, Mariotte E, Darmon M, Canet E, Merceron S, Boutboul D, Veyradier A, Galicier L, Azoulay E (2015) Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. J Thromb Haemost 13(3):380–389CrossRefPubMed
20.
go back to reference Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C et al (2010) Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 5(4):e10208CrossRefPubMedPubMedCentral Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C et al (2010) Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 5(4):e10208CrossRefPubMedPubMedCentral
21.
go back to reference Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F et al (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158(3):323–335CrossRefPubMed Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F et al (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158(3):323–335CrossRefPubMed
22.
go back to reference Lombardi AM, Fabris R, de Marinis GB, Marson P, Navaglia F, Plebani M, Vettor R, Fabris F (2014) Defective ADAMTS13 synthesis as a possible consequence of NASH in an obese patient with recurrent thrombotic thrombocytopenic purpura. Eur J Haematol 92(6):497–501CrossRefPubMed Lombardi AM, Fabris R, de Marinis GB, Marson P, Navaglia F, Plebani M, Vettor R, Fabris F (2014) Defective ADAMTS13 synthesis as a possible consequence of NASH in an obese patient with recurrent thrombotic thrombocytopenic purpura. Eur J Haematol 92(6):497–501CrossRefPubMed
23.
go back to reference Ferrari S, Knöbl P, Kolovratova V, Plaimauer B, Turecek PL, Varadi K, Rottensteiner H, Scheiflinger F (2012) Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 10(1):156–158CrossRefPubMed Ferrari S, Knöbl P, Kolovratova V, Plaimauer B, Turecek PL, Varadi K, Rottensteiner H, Scheiflinger F (2012) Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 10(1):156–158CrossRefPubMed
Metadata
Title
Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients
Authors
Giulia Berti de Marinis
Stefano Novello
Silvia Ferrari
Isabella Barzon
Irene Cortella
Maria Antonietta Businaro
Fabrizio Fabris
Anna Maria Lombardi
Publication date
01-11-2016
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2016
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1395-7

Other articles of this Issue 4/2016

Journal of Thrombosis and Thrombolysis 4/2016 Go to the issue